After a conference lacking the wow factor, biotech winners and losers emerge.
ApexOnco Front Page
Recent articles
16 September 2024
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
20 August 2024
Claudin18.2 is out, but the US big pharma opts in to a new project.
19 August 2024
The company sticks with EZH2, despite others adding EZH1 inhibition.
16 August 2024
Questions continue to swirl as the unit mulls another oncology makeover.
14 August 2024
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
12 August 2024
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
9 August 2024
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
Recent Quick take
- 24 June 2024
- 20 June 2024
- 19 June 2024
- 19 June 2024
- 18 June 2024
- 7 June 2024
- 7 June 2024
- 5 June 2024
- 5 June 2024